statistiche ricercatore

Continente	#
NA - Nord America	563
EU - Europa	423
AS - Asia	287
SA - Sud America	75
AF - Africa	32
Continente sconosciuto - Info sul continente non disponibili	31
OC - Oceania	2
Totale	1.413

Nazione	#
US - Stati Uniti d'America	527
IT - Italia	255
VN - Vietnam	75
SG - Singapore	73
CN - Cina	65
BR - Brasile	60
RU - Federazione Russa	42
HK - Hong Kong	34
NL - Olanda	30
DE - Germania	26
CA - Canada	22
FR - Francia	20
CI - Costa d'Avorio	14
FI - Finlandia	12
AT - Austria	7
BD - Bangladesh	7
MA - Marocco	7
GB - Regno Unito	6
IE - Irlanda	5
IQ - Iraq	5
JP - Giappone	5
PL - Polonia	5
SE - Svezia	5
AR - Argentina	4
EC - Ecuador	4
JM - Giamaica	4
MX - Messico	4
ID - Indonesia	3
IN - India	3
KR - Corea	3
UA - Ucraina	3
AU - Australia	2
CL - Cile	2
ES - Italia	2
LY - Libia	2
MY - Malesia	2
PY - Paraguay	2
TN - Tunisia	2
UZ - Uzbekistan	2
VE - Venezuela	2
ZA - Sudafrica	2
AE - Emirati Arabi Uniti	1
AO - Angola	1
BE - Belgio	1
CH - Svizzera	1
CR - Costa Rica	1
CW - ???statistics.table.value.countryCode.CW???	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
EG - Egitto	1
GE - Georgia	1
GP - Guadalupe	1
GT - Guatemala	1
IL - Israele	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
LT - Lituania	1
ML - Mali	1
NG - Nigeria	1
NI - Nicaragua	1
OM - Oman	1
PK - Pakistan	1
PR - Porto Rico	1
PS - Palestinian Territory	1
SV - El Salvador	1
TH - Thailandia	1
TR - Turchia	1
UY - Uruguay	1
Totale	1.383

Nome	#
1621P miRNA signature as early predictor of hyponatremia and survival in lung cancer: Preliminary results from the ISA retrospective study	205
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors	203
The Impact and Performance of the Molecular Tumor Board: Three-Year Activity in Precision Medicine for Treatment of Patients with Cancer from the Marche Region, in Italy	157
NSCLC-Pro ClustAI: A Machine Learning Model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors	151
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)	149
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?	145
miRNA signature as early predictor of hyponatremia and survival in lung cancer: preliminary results from the ISA retrospective study	144
Studio e ricerca di biomarcatori correlati con l’iponatriemia nei pazienti con tumore al polmone: genotipizzazione dei polimorfismi a singolo nucleotide ed analisi di espressione dei microRNA e dei recettori della vasopressina.	121
Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine	103
Oncological Genetic Counseling in Hereditary Breast and Ovarian Cancers and Lynch Syndrome High‐Risk Subjects: Evaluation of Efficacy and Outcomes Using the Genomics Outcome Scale	35
Totale	1.413

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	6	0	0	0	0	0	0	0	0	4	1	0	1
2022/2023	18	1	3	1	1	3	3	0	0	4	0	2	0
2023/2024	78	2	0	0	1	6	2	0	0	0	0	1	66
2024/2025	358	20	15	55	16	28	10	22	15	61	40	25	51
2025/2026	769	71	91	114	82	48	51	107	58	30	55	31	31
2026/2027	184	22	24	50	81	7	0	0	0	0	0	0	0
Totale													1.413